<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550459</url>
  </required_header>
  <id_info>
    <org_study_id>156-04-246</org_study_id>
    <secondary_id>INSIGHT</secondary_id>
    <nct_id>NCT00550459</nct_id>
  </id_info>
  <brief_title>Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate an improvement in the composite scores of validated neurocognitive tests in
      elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized, with stratification by baseline sodium &lt;130 or â‰¥ 130
      mEq/L[mmol/L] to receive either tolvaptan 15 mg tablet or matching placebo tablet at doses of
      15, 30 or 60 mg for 21 days. During this period, fluid restrictions should be loosened or
      suspended, until the subject's response to therapy can be evaluated, typically over the first
      few days of therapy. Fluid restriction may be reinstituted at any time in subjects whose
      sodium fails to improve or worsens with study therapy. A forced-titration up to 60 mg of
      study drug by day 3 to 7 will be based on the subject's serum sodium Subjects entering the
      study with a serum sodium concentration less than 130 mEq/L[mmol/L] may be fluid restricted
      if necessary at the discretion of the Investigator. Subjects should be monitored closely
      during the first 24 hours of treatment for dosing titration. The total dosing duration will
      be up to 21 days (plus 3 day treatment window). Subjects will return to the clinic on Day 22
      (+3 days) for assessments and will complete a follow-up visit on Day 28 (+2 days).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)</measure>
    <time_frame>baseline and Day 22</time_frame>
    <description>Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize &quot;yes&quot; 50 times;Choice=recognize &quot;yes&quot; or &quot;no&quot; 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right &amp; left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests</measure>
    <time_frame>baseline and Day 22</time_frame>
    <description>Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test</measure>
    <time_frame>baseline and Day 22</time_frame>
    <description>Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test</measure>
    <time_frame>baseline and Day 22</time_frame>
    <description>Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Neurocognitive Composite Score</measure>
    <time_frame>baseline and Day 22</time_frame>
    <description>Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)</measure>
    <time_frame>baseline and Day 22</time_frame>
    <description>Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postural Stability Test</measure>
    <time_frame>baseline and Day 22</time_frame>
    <description>Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Sodium; ITT Population</measure>
    <time_frame>Baseline and Day 22</time_frame>
    <description>Change from Baseline to Day 22 in Serum Sodium; ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Vital Sign Abnormalities: Blood Pressure</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of abnormal systolic &amp; diastolic blood pressure values post-baseline (abnormal systolic values: &gt;=180 mmHg + increase of &gt;=20 mmHg, &lt;= 90 mmHg + decrease &gt;=20 mmHg; abnormal diastolic values: &gt;=105 mmHg+increase of &gt;=15 mmHg, &lt;=50 mmHg + decrease of &gt;= 15 mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Vital Sign Abnormalities: Pulse Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of abnormal pulse rate post-baseline [abnormal values: &gt;=120 beats per minute (bpm) + increase of &gt;=15 bpm; &lt;=50 bpm + decrease of &gt;=15 bpm]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Vital Sign Abnormalities: Body Weight</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of &gt;=7%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Vital Sign Abnormalities: Body Temperature</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of &gt;=1.1 to &gt;=38.3 degrees Celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hematology Laboratory Abnormalities: Neutrophils</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: QT &gt;500 Milliseconds (Msec)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities (QT&gt;500 msec) post-baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change &gt; 100 msec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities: ST Segment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities: T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of potentially clinically significant ECG abnormalities: arrhythmia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet given once a day for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>15-60 mg oral tablet given once a day for 21 days.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>OPC-41061</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet given once daily for 21 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men 50 years of age or older.

          -  Serum Sodium â‰¥123 and â‰¤ 134 mEq/L [mmol/L]at screening and baseline.

          -  Subjects with serum sodium concentrations â‰¥118 and â‰¤122 mEq/L[mmol/L] at screening and
             baseline may be entered into the trial based on consultation and approval from the
             study medical monitor.

        Exclusion Criteria:

          -  Conditions or history which may present a safety concern to the subject or their
             offspring or extreme susceptibility to hypotension with sudden fluid loss (aquaresis).

          -  Hyponatremia that is acute, easily reversible, artifactual, or due to a condition not
             associated with vasopressin excess or likely to respond to aquaretic therapy.

          -  Conditions associated with an independent imminent risk of morbidity and mortality.

          -  Conditions which may confound the assessment of endpoints, history of poor compliance,
             participation in a clinical trial believed by the PI or Sponsor likely to confound
             endpoint assessments.

          -  Conditions which may confound primary endpoints of cognitive function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Verbalis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University, Washington, DC, 20007 USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarah. S. Olelewe, MD</name>
      <address>
        <city>Hawthorne</city>
        <state>California</state>
        <zip>90250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pikes Peak Cardiology</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West FL</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Nephrology Assoc. Research Center</name>
      <address>
        <city>Punta Gorda</city>
        <state>Florida</state>
        <zip>33950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockdale Medical Research Associates</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <zip>30094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otis Barnum, DO</name>
      <address>
        <city>Natchitoches</city>
        <state>Louisiana</state>
        <zip>71457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research, LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Research Associates</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne O. Wells, MD</name>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Clinical Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitchell Rosner, MD</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2007</study_first_posted>
  <results_first_submitted>August 5, 2010</results_first_submitted>
  <results_first_submitted_qc>April 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2011</results_first_posted>
  <disposition_first_submitted>February 24, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 24, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 4, 2010</disposition_first_posted>
  <last_update_submitted>April 26, 2011</last_update_submitted>
  <last_update_submitted_qc>April 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dorothee Oberdhan, Manager, Global Clinical Development</name_title>
    <organization>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</organization>
  </responsible_party>
  <keyword>Hyponatremia</keyword>
  <keyword>Cognitive</keyword>
  <keyword>Neurological Function</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>16 United States (US) sites/clinics; first subject signed informed consent on 9/11/07; last subject's final visit on 12/16/08</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablet given once daily for 21 days</description>
        </group>
        <group group_id="P2">
          <title>Tolvaptan (15-60 mg)</title>
          <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablet given once daily for 21 days</description>
        </group>
        <group group_id="B2">
          <title>Tolvaptan (15-60 mg)</title>
          <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="9.7"/>
                    <measurement group_id="B2" value="71.1" spread="10.2"/>
                    <measurement group_id="B3" value="71.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)</title>
        <description>Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize &quot;yes&quot; 50 times;Choice=recognize &quot;yes&quot; or &quot;no&quot; 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right &amp; left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data</description>
        <time_frame>baseline and Day 22</time_frame>
        <population>Analysis based upon observed cases (OC).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)</title>
          <description>Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize &quot;yes&quot; 50 times;Choice=recognize &quot;yes&quot; or &quot;no&quot; 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right &amp; left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data</description>
          <population>Analysis based upon observed cases (OC).</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.61"/>
                    <measurement group_id="O2" value="0.39" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance (ANCOVA) with factors of treatment,disease severity (&lt;130mEq/L [mmol/L] or â‰¥130mEq/L [mmol/L] at baseline),age (&lt;65, â‰¥65 to &lt;75,and â‰¥75 years) (factor with 6 Degrees of Freedom), and covariate baseline used to fit primary endpoint using the intent-to-treat (ITT) dataset. Estimated treatment effect and its 95% confidence interval (CI) provided under the model with p-value. A 2-sided alpha (0.05) applied to the primary analysis. Primary analysis based on observed cases (OC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <p_value_desc>Secondary endpoints were ordered in 5 tiers to be analyzed only when &gt;=1 of the endpoints in the prior tier were significant. Since primary endpoint not stat significant, analyses of secondary endpoint tiers presented for exploratory purposes only</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with factors of treatment, disease severity, age(6 Degrees of Freedom), and covariate baseline to fit primary endpoint using the ITT dataset.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests</title>
        <description>Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population</description>
        <time_frame>baseline and Day 22</time_frame>
        <population>ITT population with OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests</title>
          <description>Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population</description>
          <population>ITT population with OC</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.86"/>
                    <measurement group_id="O2" value="0.33" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <p_value_desc>ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test</title>
        <description>Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population</description>
        <time_frame>baseline and Day 22</time_frame>
        <population>ITT population with OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test</title>
          <description>Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population</description>
          <population>ITT population with OC</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.36"/>
                    <measurement group_id="O2" value="0.31" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.27</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test</title>
        <description>Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population</description>
        <time_frame>baseline and Day 22</time_frame>
        <population>ITT population with OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test</title>
          <description>Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population</description>
          <population>ITT population with OC</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.75"/>
                    <measurement group_id="O2" value="0.48" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <p_value_desc>ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Neurocognitive Composite Score</title>
        <description>Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population</description>
        <time_frame>baseline and Day 22</time_frame>
        <population>ITT population with OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Neurocognitive Composite Score</title>
          <description>Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population</description>
          <population>ITT population with OC</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.39"/>
                    <measurement group_id="O2" value="0.30" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)</title>
        <description>Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population</description>
        <time_frame>baseline and Day 22</time_frame>
        <population>ITT population with OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)</title>
          <description>Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population</description>
          <population>ITT population with OC</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="5.63"/>
                    <measurement group_id="O2" value="-0.43" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.51</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.02</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postural Stability Test</title>
        <description>Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population</description>
        <time_frame>baseline and Day 22</time_frame>
        <population>ITT population with LOCF (this group includes missing values)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postural Stability Test</title>
          <description>Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population</description>
          <population>ITT population with LOCF (this group includes missing values)</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="4.68"/>
                    <measurement group_id="O2" value="-0.35" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.83</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.04</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Sodium; ITT Population</title>
        <description>Change from Baseline to Day 22 in Serum Sodium; ITT population</description>
        <time_frame>Baseline and Day 22</time_frame>
        <population>ITT population with OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Sodium; ITT Population</title>
          <description>Change from Baseline to Day 22 in Serum Sodium; ITT population</description>
          <population>ITT population with OC</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="3.51"/>
                    <measurement group_id="O2" value="7.04" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.89</ci_lower_limit>
            <ci_upper_limit>6.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Vital Sign Abnormalities: Blood Pressure</title>
        <description>Incidence of abnormal systolic &amp; diastolic blood pressure values post-baseline (abnormal systolic values: &gt;=180 mmHg + increase of &gt;=20 mmHg, &lt;= 90 mmHg + decrease &gt;=20 mmHg; abnormal diastolic values: &gt;=105 mmHg+increase of &gt;=15 mmHg, &lt;=50 mmHg + decrease of &gt;= 15 mmHg)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Vital Sign Abnormalities: Blood Pressure</title>
          <description>Incidence of abnormal systolic &amp; diastolic blood pressure values post-baseline (abnormal systolic values: &gt;=180 mmHg + increase of &gt;=20 mmHg, &lt;= 90 mmHg + decrease &gt;=20 mmHg; abnormal diastolic values: &gt;=105 mmHg+increase of &gt;=15 mmHg, &lt;=50 mmHg + decrease of &gt;= 15 mmHg)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Vital Sign Abnormalities: Pulse Rate</title>
        <description>Incidence of abnormal pulse rate post-baseline [abnormal values: &gt;=120 beats per minute (bpm) + increase of &gt;=15 bpm; &lt;=50 bpm + decrease of &gt;=15 bpm]</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Vital Sign Abnormalities: Pulse Rate</title>
          <description>Incidence of abnormal pulse rate post-baseline [abnormal values: &gt;=120 beats per minute (bpm) + increase of &gt;=15 bpm; &lt;=50 bpm + decrease of &gt;=15 bpm]</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Vital Sign Abnormalities: Body Weight</title>
        <description>Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of &gt;=7%)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Vital Sign Abnormalities: Body Weight</title>
          <description>Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of &gt;=7%)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Vital Sign Abnormalities: Body Temperature</title>
        <description>Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of &gt;=1.1 to &gt;=38.3 degrees Celsius)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Vital Sign Abnormalities: Body Temperature</title>
          <description>Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of &gt;=1.1 to &gt;=38.3 degrees Celsius)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin</title>
        <description>Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin</title>
          <description>Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)</title>
        <description>Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)</title>
          <description>Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes</title>
        <description>Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes</title>
          <description>Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hematology Laboratory Abnormalities: Neutrophils</title>
        <description>Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hematology Laboratory Abnormalities: Neutrophils</title>
          <description>Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)</title>
        <description>Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)</title>
          <description>Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid</title>
        <description>Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid</title>
          <description>Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol</title>
        <description>Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol</title>
          <description>Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose</title>
        <description>Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose</title>
          <description>Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium</title>
        <description>Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium</title>
          <description>Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QT &gt;500 Milliseconds (Msec)</title>
        <description>Incidence of potentially clinically significant ECG abnormalities (QT&gt;500 msec) post-baseline</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QT &gt;500 Milliseconds (Msec)</title>
          <description>Incidence of potentially clinically significant ECG abnormalities (QT&gt;500 msec) post-baseline</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval</title>
        <description>Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change &gt; 100 msec)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval</title>
          <description>Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change &gt; 100 msec)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec</title>
        <description>Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec</title>
          <description>Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec</title>
        <description>Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec</title>
          <description>Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment</title>
        <description>Incidence of potentially clinically significant ECG abnormalities: ST Segment</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment</title>
          <description>Incidence of potentially clinically significant ECG abnormalities: ST Segment</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave</title>
        <description>Incidence of potentially clinically significant ECG abnormalities: T wave</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave</title>
          <description>Incidence of potentially clinically significant ECG abnormalities: T wave</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)</title>
        <description>Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)</title>
          <description>Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia</title>
        <description>Incidence of potentially clinically significant ECG abnormalities: arrhythmia</description>
        <time_frame>28 days</time_frame>
        <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet given once daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan (15-60 mg)</title>
            <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia</title>
          <description>Incidence of potentially clinically significant ECG abnormalities: arrhythmia</description>
          <population>Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 Days</time_frame>
      <desc>collection/elicitation of adverse event incidence</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet given once daily for 21 days</description>
        </group>
        <group group_id="E2">
          <title>Tolvaptan (15-60 mg)</title>
          <description>Tolvaptan tablet 15-60 mg given once daily for 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine output increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot study powered only for serum Na+ improvements. Trial lacked sufficient power to detect changes in neurocognitive test scores and SF-12 and HDS outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Frank Czerwiec, MD, PhD; Sr. Director, Global Clinical Development</name_or_title>
      <organization>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</organization>
      <phone>(240) 683-3523</phone>
      <email>frank.czerwiec@otsuka.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

